Have a medical question?
- Learn about your treatment options
- Ask questions about your diagnosis
- Get doctor recommendations
Written By: David Statman
Chemotherapy is a frequently used treatment for mesothelioma. It is a treatment option that can be given to patients before, during or after surgery, or in cases when surgery isn’t possible. This treatment is considered the baseline for survival and safety when the FDA considers approving new therapies for mesothelioma.
Chemotherapy for malignant mesothelioma is an important treatment option that aims to eliminate or control cancer cells in the body. It is often used to improve the chances of extending survival, either on its own or as part of a combination therapy that includes surgery or radiation. The most common and FDA-approved chemotherapy drugs for mesothelioma are cisplatin and pemetrexed. These drugs work by targeting rapidly dividing cancer cells, with cisplatin interfering with their DNA and pemetrexed inhibiting crucial processes for cell growth. The combination of these drugs has been shown to increase median survival times compared to using either drug alone.
Patients typically receive chemotherapy through an intravenous (IV) infusion in a hospital, clinic, or outpatient center. In some cases, special methods like heated intraoperative chemotherapy or dwell therapy may be used to deliver higher concentrations directly to the tumor site while minimizing side effects elsewhere. Chemotherapy can be given in cycles, usually once every three weeks, with recovery periods in between. Preparing for treatment involves discussions with medical professionals about potential side effects such as fatigue, nausea, mouth sores, and changes in taste. Patients are encouraged to plan for support at home, stay hydrated, eat nutritious foods, and rest to help manage side effects effectively.
While chemotherapy can cause side effects, many are manageable with medical guidance. Common issues include nausea, fatigue, and weakened immunity, which require careful monitoring and supportive care. Some patients may experience cognitive changes known as "chemo brain," which can temporarily affect memory and concentration. Emerging treatments and clinical trials are exploring other chemotherapy drugs and techniques, such as oral pills and pressurized spray therapies, to improve effectiveness and reduce side effects. Overall, with proper management and coordination with healthcare providers, chemotherapy remains a foundational treatment that can help extend life and improve quality of life for those facing mesothelioma.
Chemotherapy is a treatment option designed to eliminate cancer cells, particularly those that grow and divide more rapidly than normal, such as diseased mesothelial cells in mesothelioma.
When mesothelioma develops, it spreads by diseased cells replicating at an accelerated rate. Chemotherapy works to destroy these cancer cells and can help to extend a patient’s life.
This treatment involves the use of cytotoxic (anti-cancer) drugs, which are typically administered intravenously through an IV drip. Once in the bloodstream, these drugs target areas of rapid cell growth, disrupting the replication process and causing cancer cells to die.
Chemotherapy is the most accessible treatment for mesothelioma. Patients can receive treatment at a local hospital, a cancer center, an outpatient medical clinic or an infusion center.
In 2004, the FDA approved cisplatin and pemetrexed for malignant mesothelioma. There are several studies using pemetrexed in combination with cisplatin that demonstrate a prolonged survival in mesothelioma patients.
Cisplatin, commonly known by its brand name Platinol, is a platinum-based chemotherapy drug. It belongs to the alkylating agent class, which is a group of drugs that interfere with the DNA of cancer cells, preventing them from growing and dividing.
Pemetrexed, sold under the brand name Alimta, is a chemotherapy drug classified as an antifolate antineoplastic agent. This means it works by inhibiting the production of folate, a vitamin essential for DNA and RNA synthesis in rapidly dividing cells. By disrupting this process, pemetrexed prevents cancer cells from growing and multiplying, ultimately leading to their destruction.
According to the U.S. National Library of Medicine, the pemetrexed injection is administered for 10 minutes and repeated once every three weeks. This administration requires much less time than standard intravenous chemotherapy (usually lasting at least one hour).
If you have been diagnosed with mesothelioma and are considering chemotherapy treatment, follow these three steps to find the best treatment options:
After receiving a diagnosis, contact a mesothelioma specialist to learn about your treatment options. You might be a candidate for surgery, which can provide longer survival than chemotherapy alone.
Research the chemotherapy drugs used for mesothelioma. Learn more about chemotherapy, the risks, the benefits, and the potential side effects. Discuss all the details with your mesothelioma specialist. The doctor will help you determine if this is the right choice to fight your mesothelioma and maintain your quality of life.
Plan your treatment with a specialist. Chemotherapy involves infusion cycles, or rounds, which usually occur once every 3 weeks with a rest period in between. Your doctor will develop a treatment plan to determine how many cycles you will need.
Intravenous chemotherapy, also called systemic chemotherapy, is the main type of mesothelioma chemotherapy. It’s also called systemic chemotherapy. It involves delivering chemotherapy medications through an IV into a vein or port. The drugs travel through the bloodstream to find and kill cancer cells.
Other types of mesothelioma chemotherapy are:
Dwell chemotherapy is similar to the HIPEC, where chemotherapy drugs are delivered directly into the chest or abdominal cavity. The ports for dwell treatment are placed in surgery but left in place for extended periods of time. This allows doctors the ability to deliver localized chemotherapy continuously or in cycles for days, weeks or months after surgery.
Oral chemotherapy for mesothelioma is currently under investigation, with one promising drug being Olaparib, marketed under the brand name Lynparza.
A clinical trial at the University of Chicago Medicine is testing the effectiveness and safety of olaparib for mesothelioma patients. Participants receive the drug orally every two weeks, with treatment cycles spanning 28 days. The trial aims to evaluate how well the drug controls tumor growth, its potential to improve survival rates, and the tolerability of side effects.
Spray chemotherapy, or pressurized intraperitoneal aerosol chemotherapy (PIPAC), is another type of chemotherapy being studied in clinical trials.
A study in France used it for peritoneal mesothelioma to see if patients could have cytoreduction/HIPEC surgery afterward. In the study, 13 patients received chemotherapy spray and all of them had surgery after. The average progression-free survival for the patients was 33.7 months.
Multimodal therapy is a combination of treatment options used to achieve optimal results. Mesothelioma chemotherapy is often part of a multimodal approach to treating this rare cancer.
Chemotherapy can be used before or after surgery. This multimodal option has presented improved survival rates.
The FDA approved Optune Lua, which is a tumor treating fields device that sends electrical waves, or fields, through the chest to kill cancer cells. This mesothelioma treatment is FDA-approved when paired with systemic chemotherapy.
Other combinations of mesothelioma multimodal therapy pair chemotherapy with:
Immunotherapy
Radiation therapy
Photodynamic therapy
Receiving mesothelioma chemotherapy involves planning and preparation. Understanding and planning for potential side effects, the possible need for caregivers, and prioritizing healthy habits can set yourself up for success.
Before going to the hospital for treatment, patients should:
The doctor, nurse or another member of the medical team will provide the information you need to fully prepare you for your mesothelioma chemotherapy treatment. It is important to take notes, ask questions and understand what to expect.
After the mesothelioma chemotherapy treatment, the nurse will explain possible side effects and instruct you to call the doctor with any new or worsening symptoms or side effects. Many of the symptoms and side effects from chemotherapy can be managed, but the medical team must be alerted right away.
Chemotherapy can weaken the body’s immune system. Important things to know are:
Talk with your doctor about post-treatment precautions, recommendations, and when to report changes or concerns.
There are a few steps to receiving mesothelioma chemotherapy. These steps may change depending on the type of chemotherapy:
Before starting treatment, patients undergo blood tests to ensure they are a good candidate for chemotherapy. These tests reveal the patient’s overall health and health of certain organs, such as the liver and kidneys. Patients also have their vital signs monitored, such as blood pressure, pulse, respiratory rate and temperature.
For intravenous chemotherapy, a nurse inserts a catheter into the patient’s arm or implanted port. If the patient is receiving heated intraoperative chemotherapy, the two ports/catheters are inserted into their abdomen or chest during surgery.
Chemotherapy is delivered into the patient’s body, either through the IV or port. Intravenous chemotherapy delivers drugs through an IV drip and can last up to an hour. The total infusion time may be longer depending on other IV medications or hydration needed for the treatment. Heated intraoperative chemotherapy is administered through ports/catheters, as the patient is rocked side to side to ensure the distribution of the therapy. The tumors are exposed to chemotherapy for an extended amount of time.
The medical staff removes the delivery method from the patient, either the IV catheter or intraoperative ports/catheters.
A nurse monitors the patient closely after treatment. The patient’s blood pressure, pulse, breathing and temperature are all evaluated for any changes. If intravenous chemotherapy was used, they may check the blood count to record the levels of red and white blood cells. After surgery with intraoperative chemotherapy, the patient remains in the hospital for postoperative recovery.
Intravenous chemotherapy is typically given once every 3 weeks with a rest period in between. The number of cycles may vary for each patient.
Some mesothelioma specialists use dwell chemotherapy, which is different from intravenous chemotherapy. These are the steps for dwell chemotherapy:
The medical team leaves the ports in the patient following surgery with heated intraoperative chemotherapy.
Some patients receive EPIC, or “early postoperative intraperitoneal chemotherapy.” This usually occurs a few days after surgery, when the patient is likely still recovering in the hospital.
Patients may be required to stay in the hospital for a few days after they receive this treatment.
NIPEC, or normothermic intraperitoneal chemotherapy, is a form of dwell chemotherapy where the chemotherapy drugs are not heated (like with HIPEC). With this therapy, the patient will return to the medical facility weeks after surgery to have chemotherapy delivered in the chest or abdominal cavity. The length of this procedure may vary depending on the patient and type of chemotherapy ordered by the doctor.
Like chemotherapy for lung cancer or other types of cancer, chemotherapy for mesothelioma may cause side effects. There are nearly 50 potential side effects of chemotherapy. Some are manageable and mild, while others can be severe and cause serious complications.
Some of the chemotherapy side effects for mesothelioma are:
Body aches
Mouth sores
Fatigue
Changes
to taste
Nausea
and vomiting
Loss of weight
and appetite
Chemotherapy drugs may also lead to more severe side effects:
Eating smaller portions more often, taking regular naps, avoiding fatty foods, and regular light exercise are just a few ways to minimize these side effects.
Antiemetic drugs, which are drugs that reduce nausea and vomiting, are often prescribed for patients receiving chemotherapy. Doctors may recommend patients take these medications as a preventative measure to avoid nausea and vomiting, which can lead to more serious complications like weight loss, weakness and malnutrition.
“Chemo brain” refers to cognitive changes that some people experience during or after chemotherapy treatment. It often involves difficulties with memory, concentration, multitasking, and processing information.
While the exact cause isn’t fully understood, it’s thought to result from a combination of chemotherapy effects, fatigue, stress, and other factors. Symptoms can vary in severity and duration, with most improving over time. Strategies like mental exercises, organization tools, and lifestyle adjustments can help manage the condition.
Symptoms of chemo brain often improve within 9-12 months. However, there is a chance that individuals may have long-term effects. Some of the ways to prevent or overcome chemo brain include:
The top chemotherapy drugs for mesothelioma are cisplatin and pemetrexed. They are the only two approved by the FDA for this cancer.
Other mesothelioma chemotherapy medications used in clinical trials or as substitutes are:
Carboplatin is often a substitute when patients have a reaction to cisplatin. It can help some patients with side effects. Gemcitabine and vinorelbine are still under investigation and testing. These chemotherapy drugs are used for pleural mesothelioma.
For peritoneal mesothelioma, the combination of cisplatin and pemetrexed is used as a systemic chemotherapy treatment. When surgery is a treatment option, doctors may opt for the chemotherapy drugs doxorubicin and mitomycin during cytoreductive surgery with heated intraperitoneal chemotherapy. For this, doctors may use the chemotherapy drugs doxorubicin and mitomycin.
The average survival for patients treated with standard (systemic) mesothelioma chemotherapy on its own is 12-17 months. The variance depends on factors such as patient selection and the type of mesothelioma.
Doctors have begun administering a combination of drugs to achieve improved survival rates for mesothelioma. The most common pairing is pemetrexed and cisplatin. A study published in the Journal of Thoracic Disease reported a median survival of 12 months for systemic cisplatin and pemetrexed. Patients receiving cisplatin without pemetrexed had a median survival of 9 months.
Peritoneal mesothelioma has a slightly better survival rate with systemic chemotherapy. One study reported a median survival of 17 months for patients who received only this treatment.
Chemotherapy can increase survival, diminish symptoms and improve quality of life. Doctors have not found a cure for mesothelioma, but chemotherapy is one option proven to help people with this rare cancer.
The main types of chemotherapy for mesothelioma are systemic (intravenous) and intraoperative. Systemic chemotherapy is the well-known approach where doctors administer the drugs into the vein. Intraoperative is a more modern approach where doctors deliver the drugs, usually heated, in liquid form directly into the chest or abdominal cavity, where tumors develop.
Pemetrexed and cisplatin are approved by the U.S. Food and Drug Administration for mesothelioma. When paired together, they increased survival by four months compared to only taking cisplatin. Some patients respond better to carboplatin than cisplatin. Other chemotherapy drugs used in clinical studies are:
Chemotherapy takes 2-3 hours for the systemic intravenous method. Intraoperative chemotherapy is usually 1-2 hours. Systemic chemotherapy is broken up into “rounds” or “cycles.” Each cycle is given once every 3 weeks with a rest period in between treatment. The number of cycles depends on the stage of the cancer and how well a patient handles treatment.